University of Pittsburgh Cancer Institute (UPCI)

Diagnostic and Prognostic Markers

MicroscopeBOCP members are actively identifying, developing, and characterizing novel diagnostic and prognostic markers for breast and ovarian cancers.

Selected Publications

  • Eight radiologists who specialize in breast imaging retrospectively reviewed 217 consecutively accrued lesions in 182 patients who underwent diagnostic mammography and digital breast tomosynthesis (DBT) to compare the diagnostic performance of these two methods in the classification of masses, distortions, and asymmetries. They found that DBT significantly improved diagnostic accuracy for noncalcified lesions compared with supplemental mammographic views. (Zuley et al., Radiology. 266(1):89-95, 2013).
  • Endometriosis, a largely benign, chronic inflammatory disease, is an independent risk factor for endometrioid and clear cell epithelial ovarian tumors. Three distinct miRNA signatures were identified with reliable differential expression between healthy individuals, patients with endometriosis, and patients with endometriosis-associated ovarian cancer (EAOC), which may serve as highly specific and sensitive diagnostic biomarkers to discriminate between these cases. (Suryawanshi et al., Clin Cancer Res. 19(5):1213-24, 2013).
  • Oncotype DX is a commercial assay frequently used for making chemotherapy decisions in estrogen receptor (ER)-positive breast cancers. Using a set of 817 cases with clinical Oncotype DX scores, an equation was developed based upon standard morphoimmuologic variables that can predict recurrence risk with 97-100% accuracy (Klein et al., Mol Pathol. 26(5):658-64, 2013). The 'Magee equation' is now reported on all breast cancer cases at UPCI and reviewed at tumor board.
  • Prognostic performance of an optimized model of Breast Cancer Index (BCI), an algorithmic gene expression-based signature, was examined for prediction of early (0-5 years) and late (>5 years) risk of distant recurrence in patients with estrogen receptor-positive (ER(+)), lymph node-negative (LN(-)) tumors. While BCI shows similar performance to Oncotype DX in predicting early recurrence, it was found that BCI is also an excellent predictor of late recurrence in patients who have received 5 years of adjuvant tamoxifen therapy (Zhang et al., Clin Cancer Res. 19(15):4196-205, 2013).

Members

Ahrendt, Gretchen, MD
Surgery
Huang, Xin, PhD
Obstetrics, Gynecology, & Reproductive Sciences
Berg, Wendie, MD, PhD
Radiology
Jankowitz, Rachel, MD
Medicine
Bhargava, Rohit, MD
Pathology
Lee, Adrian, PhD
Pharmacology & Chemical Biology
Brufsky, Adam, MD, PhD
Medicine
Nishikawa, Robert, PhD, FAAPM
Radiology
Chandran, Uma, PhD, MSIS
Biomedical Informatics
Oesterreich, Steffi, PhD
Pharmacology & Chemical Biology
Dabbs, David, MD
Pathology
Sumkin, Jules, DO
Radiology
Edwards, Robert, MD
Obstetrics, Gynecology, & Reproductive Sciences
Vlad, Anda, MD, PhD
Obstetrics, Gynecology, & Reproductive Sciences
Elishaev, Esther, MD
Pathology
Zheng, Bin, PhD
Radiology
Gur, David, ScD
Radiology
Zuley, Margarita, MD
Radiology
Hakim, Christiane, MD
Radiology